Clinical trial
To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With…
NCT00189319 · MEDA Pharma GmbH & Co. KG, Industry · Completed
Key facts
| NCT number | NCT00189319 |
|---|---|
| Title | To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation |
| Official title | Impact of Oral Controlled Release Flecainide Acetate Capsules on Health-Related QoL in Patients With Paroxysmal Atrial Fibrillation |
| Lead sponsor | MEDA Pharma GmbH & Co. KG, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Atrial Fibrillation |
| Intervention type | Drug |
| Interventions | Flecainide controlled release |
| Enrollment | 200 |
| Start date | Sep 1, 2003 |
| First posted | Sep 19, 2005 |
| Last update posted | Feb 7, 2022 |
| Countries | France |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: